| [1] |
Bray F, Ferlay J, Soerjomataram L, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014[J]. Chin J Cancer Res, 2018, 30(1): 1-12.
|
| [3] |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
|
| [4] |
Zhang SW, Sun KX, Zheng RS, et al. Cancer incidence and mortality in China, 2015[J]. JNCC, 2021, 1(1): 2-11.
|
| [5] |
Nakamura Y, Kawazoe A, Lordick F, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm[J]. Nat Rev Clin Oncol, 2021. Epub ahead of print
|
| [6] |
Song J, Lee HJ, Cho GS, et al. Recurrence following laparoscopy-assisted gastrectomy for gastric cancer: A multicenter retrospective analysis of 1 417 patients[J]. Ann Surg Oncol, 2010, 17(7): 1777-1786.
|
| [7] |
Badgwell B, Cormier JN, Xing Y, et al. Attempted salvage resection for recurrent gastric orgastroesophageal cancer[J]. Ann Surg Oncol, 2009, 16(1): 42-50.
|
| [8] |
Lin EM, Gong J, Klempner SJ, et al. Advances in immunooncology biomarkers for gastroesophageal cancer: programmed death ligand 1, microsatellite instability, and beyond[J].World J Gastroenterol, 2018, 24(25): 2686-2697.
|
| [9] |
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer[J]. CA Cancer J Clin, 2021, 71(3): 264-279.
|
| [10] |
National Comprehensive Cancer Network. Guidelines Gastric Cancer. Version 1.2021[S/OL].
|
| [11] |
中国抗癌协会肿瘤标志专业委员会遗传性肿瘤标志物协作组，中国抗癌协会肿瘤病理专业委员会分子病理协作组. 肿瘤突变负荷检测及临床应用中国专家共识(2020年版)[J]. 中国癌症防治杂志, 2020, 12(5): 485-494.
|
| [12] |
McKean WB, Moser JC, Rimm D, et al. Biomarkers in precision cancer immunotherapy: promise and challenges[J]. Am Soc Clin Oncol Educ Book, 2020, 40: e275-e291.
|
| [13] |
NCCN Management of Immunotherapy-Related Toxicities. Version 1.2021[S/OL].
|
| [14] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)胃癌诊疗指南2020[M].北京: 人民卫生出版社, 2020.
|
| [15] |
Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial[J]. JAMA Oncol, 2018, 4(5): e180013.
|
| [16] |
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer re-fractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471.
|
| [17] |
Chen LT, Satoh T, Ryu MH, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastric esophageal junction cancer (ATTRACTION-2): 2-year update data[J]. Gastric Cancer, 2020, 23(3): 510-519.
|
| [18] |
Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018, 24(9): 1449-1458.
|
| [19] |
Tabernero J, Van Cutsem E, Bang Y, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for firstline treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the Phase 3 KEYNOTE-062 Study[J]. Ann Oncol, 2019, 30(suppl 4): iv152-iv153.
|
| [20] |
Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase b/ clinical trial NCT02915432[J]. Ann Oncol, 2019, 30(9): 1479-1486.
|
| [21] |
Greally M, Chou JF, Chatila WK, et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer[J]. Clin Cancer Res, 2019, 25(20): 6160-6169.
|
| [22] |
Mishima S, Kawazoe A, Nakamura Y, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer[J]. J Immunother Cancer, 2019, 7(1): 24.
|
| [23] |
Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage Ⅱ/Ⅲ gastric cancer: post hoc analysis of the CLASSIC randomized controlled study[J]. Ann Surg, 2019, 270(2): 309-316.
|
| [24] |
Moehler M, Shitara K, Garrido M, et al. Nivolumab plus chemotherapy versus chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: first results of the CheckMate 649 study[EB/OL]. 2020, ESMO, LBA6.
|
| [25] |
FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer. Retrieved April 16, 2021, from https://www.prnewswire.com/news-releases/fda-approves-first-immunotherapy-for-initial-treatment-of-gastric-cancer-301270710.html.
|
| [26] |
Boku N, Ryu MH, Oh DY, et al. Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/ gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study[J]. Ann Oncol, 2020, 31(4): S1192.
|
| [27] |
Peng Z, Wei J, Wang F, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2021, 27(11): 3069-3078.
|
| [28] |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Retrieved May 5, 2021, from.
|